Trials / Unknown
UnknownNCT02194634
Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 248 (estimated)
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess safety and efficacy of intravitreal injection of Conbercept on visual acuity and anatomic outcomes in patients with diabetic macular edema (DME) .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Conbercept | Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed. |
| OTHER | Sham injection | Sham intravitreal injection at first month, then repeated as needed. |
| PROCEDURE | Laser | Laser treatment at first month, then repeated as needed. |
| OTHER | Sham laser | Sham laser at first month, then repeated as needed. |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-12-01
- Completion
- 2017-09-01
- First posted
- 2014-07-18
- Last updated
- 2016-01-06
Locations
17 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02194634. Inclusion in this directory is not an endorsement.